Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 21, 743-748, July 1, 1961]
© 1961 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vogel, A. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vogel, A. W.

Tumor and Marrow Damage Occurring from Methotrexate, Monofluoromethotrexate, Difluoromethotrexate, and Dichloromethotrexate

Adolph W. Vogel

( Experimental Therapeutics Research, American Cyanamid Company, Pearl River, N.Y.)

The effects of methotrexate, 3',5'-dichloromethotrexate (DCM), and two new antifolic acid compounds, monofluoromethotrexate (MFM) and difluoromethotrexate (DFM), on the C3H mouse marrow count and a transplanted tumor, the 6C3HED lymphosarcoma, were studied. The data were presented in the following forms: plots of the regression lines of marrow counts and tumor weight responses against dose of compound used; slopes of the regression lines; relative potencies of the bone marrow destruction; and antitumor activity as compared with methotrexate as a standard.

MFM caused the greatest damage to the marrow; DFM was almost equal to methotrexate in its destructive effect on the marrow. DCM caused no detectable destruction of the marrow in a dose range of 6.6 to 33 mg/kg; at a range of 75 to 168 mg/kg mild destruction was detected. All compounds caused suppression of tumor weight with increase in dose. The slopes of the plots of the regression lines of tumor weight against dose were all close to –1.0. The relative potency of the antitumor activity of MFM and DFM and DCM compared with that of methotrexate showed that it took 3, 19, or 99 times as much compound, respectively, to cause the same amount of tumor suppression as resulted from methotrexate (dose range, .198–2.25). The marrow destructive effect required 1.7, 31, or 200 times as much MFM, DFM, or DCM as methotrexate, respectively.

DCM, 33 mg/kg/day for 54 days or a total dose of 1782 mg/kg, did not cause depression of the marrow, white, red, or peripheral blood differential counts.

Received 11/26/60.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1961 by the American Association for Cancer Research.